Johnson and Johnson ( J&J) Medical Devices Companies, through its division Apsis, has acquired French surgical technologies developer Orthotaxy for an undisclosed amount.
The deal includes a robotic-assisted surgery solution currently being developed by Orthotaxy for both total and partial knee replacement.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
J&J intends to advance this solution as a cost-effective, time-efficient and easy-to-use option for a wide variety of orthopaedic surgery procedures and care settings.
The firm will primarily devise its complete orthopaedic solution based on the Orthotaxy’s technology. The new solution will be designed to leverage enabling technologies to personalise and optimise surgical procedures.
J&J’s orthopaedics unit DePuy Synthes group chairman Ciro Rӧmer said: “Our goal is to bring to market a robotic-assisted surgery technology that is an integral part of a comprehensive orthopaedics platform, delivering value to patients, physicians and healthcare providers across the episode of care.
“The team at Orthotaxy has significant expertise and passion in developing this platform, and we aspire to bring to market a differentiated technology that helps improve clinical outcomes and increases patient satisfaction.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataJ&J believes that the latest deal is in line with its goal to develop a comprehensive digital surgery platform for better patient outcomes and standard of care.
The firm plans to further develop digital technology solutions that will deliver transformative care.
In addition to products for general surgery, J&J’s medical device portfolio includes orthopaedic and cardiovascular disease solutions.
